Receive a weekly summary and discussion of the top papers of the week by leading researchers in the field.

In Xenotransplantation ; h5-index 27.0

Islet transplantation is poised to play an important role in the treatment of type 1 diabetes mellitus (T1DM). However, there are several challenges limiting its widespread use, including the instant blood-mediated inflammatory reaction, hypoxic/ischemic injury, and the immune response. Mesenchymal stem/stromal cells (MSCs) are known to exert regenerative, immunoregulatory, angiogenic, and metabolic properties. Here, we review recent reports on the application of MSCs in islet allo- and xenotransplantation. We also document the clinical trials that have been undertaken or are currently underway, relating to the co-transplantation of islets and MSCs. Increasing evidence indicates that co-transplantation of MSCs prolongs islet graft survival by locally secreted protective factors that reduce immune reactivity and promote vascularization, cell survival, and regeneration. MSC therapy may be a promising option for islet transplantation in patients with T1DM.

Qu Zepeng, Lou Qi, Cooper David K C, Pu Zuhui, Lu Ying, Chen Jiao, Ni Yong, Zhan Yongqiang, Chen Jun, Li Zhenjie, Zhan Naiyang, Zeng Yi, Tu Ziwei, Cao Huayi, Dai Yifan, Cai Zhiming, Mou Lisha

2021-Feb-10

allotransplantation, cell therapy, islets, mesenchymal stem cells, mesenchymal stromal cells, type 1 diabetes mellitus, xenotransplantation